<DOC>
	<DOCNO>NCT00489411</DOCNO>
	<brief_summary>RATIONALE : Duloxetine may lessen peripheral neuropathy cause chemotherapy . It yet know whether duloxetine effective placebo treat peripheral neuropathy cause chemotherapy . PURPOSE : This randomized phase III trial study duloxetine see well work compare placebo treat peripheral neuropathy cause chemotherapy patient cancer .</brief_summary>
	<brief_title>Duloxetine Treating Peripheral Neuropathy Caused Chemotherapy Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy duloxetine hydrochloride cancer patient painful chemotherapy-induced ( taxane platinum agent ) peripheral neuropathy . Secondary - Determine influence drug peripheral neuropathy-related functional status quality life patient . - Describe difference duloxetine hydrochloride efficacy use treat pain cause chemotherapy-induced peripheral neuropathy base neurotoxic drug class . OUTLINE : This randomize , double-blind , placebo-controlled , crossover study . Patients stratify accord prior neurotoxic agent ( paclitaxel v oxaliplatin v taxane agent without paclitaxel v platinum agent [ cisplatin ] without oxaliplatin ) high risk develop painful chemotherapy-induced peripheral neuropathy ( vs yes ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral duloxetine hydrochloride twice daily week 1-6 . After 1-week rest period , patient cross receive oral placebo twice daily week 8-13 . - Arm II : Patients receive oral placebo twice daily week 1-6 . After 1-week rest period , patient cross receive oral duloxetine hydrochloride twice daily week 8-13 . Patients complete pain quality life questionnaire , include BPI-SF weekly FACT/GOG-NTX EORTC QLQ-C30 questionnaire , week 1 , 6 , 8 , 13 . After completion study treatment , patient follow 2 week .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer CNS malignancy allow exception leptomeningeal carcinomatosis Must painful sensory chemotherapyinduced peripheral neuropathy ( CIPN ) result prior treatment singleagent taxane platinum agent ( paclitaxel , docetaxel , nabpaclitaxel , oxaliplatin , cisplatin ) ( may receive drug class ) CIPN &gt; grade 1 measure NCICTCAE v 4.0 Average neuropathic pain score ≥ 4 Patients follow illness know cause peripheral neuropathy eligible , provide evidence neuropathy illness : Diabetes mellitus Peripheral vascular disease HIV infection Significant degenerative familial neurologic disorder know cause peripheral neuropathy No clinical subclinical neuropathy nerve compression injury ( i.e. , carpal tunnel syndrome , brachial plexopathy , spinal stenosis , spinal nerve root compression ) PATIENT CHARACTERISTICS : AST ≤ 3 time upper limit normal Total bilirubin ≤ normal Creatinine clearance &gt; 30 mL/min Not pregnant nursing Able take oral enteral medication No history seizure disorder No diagnosis ethanol addiction dependence within past 10 year No history narrowangle glaucoma None follow : History suicidal thought Symptoms history schizophrenia , bipolar disease , major depression Serious eat disorder bulimia anorexia electrolyte imbalance likely PRIOR CONCURRENT THERAPY : At least 3 month since prior concurrent taxane platinum agent At least 14 day since prior concurrent monoamine oxidase inhibitor antidepressants No prior concurrent neurotoxic drug ( e.g. , vincristine , vinblastine , cytarabine , thalidomide , bortezomib , carboplatin , procarbazine ) No concurrent anticonvulsants No concurrent B E vitamin supplementation dos great recommend daily allowance ( RDA ) Centrum ( standard formula ) OneADay `` essential '' formula contain 100 % RDA vitamins B6 , E , B12 allow Other multivitamin allow provide contain 100 % RDA B vitamins vitamin E No concurrent treatment ( pharmacologic ) depression</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>pain</keyword>
	<keyword>peripheral neuropathy</keyword>
</DOC>